XENE peer analysis
Xenon Pharmaceuticals (XENE) against its competitors: price, today's move, 1-year return and market value side by side.
XENE and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ACAD Acadia Pharmaceuticals | $20.47 | -0.58% | -9.98% | $3.55B |
| AVXL Anavex Life Sciences | $1.19 | -8.46% | -85.18% | $110.31M |
| AXSM Axsome Therapeutics | $136.07 | -5.79% | 2.19% | $7.57B |
| DNLI Denali Therapeutics | $18.86 | -0.40% | 15.17% | $3.03B |
| JAZZ Jazz Pharmaceuticals | $214.64 | -0.62% | 57.48% | $14.02B |
| NBIX Neurocrine Biosciences | $156.00 | 6.78% | 13.01% | $14.85B |
| NMRA Neumora Therapeutics | $0.37 | -5.43% | -87.47% | – |
| PRAX Praxis Precision Medicines | $273.58 | -4.32% | 36.11% | – |
| RAPP Rapport Therapeutics | $25.10 | 0.20% | -6.62% | – |
| SUPN Supernus Pharmaceuticals | $41.92 | 0.19% | -25.81% | $2.44B |
| XENE Xenon Pharmaceuticals | $37.59 | 0.48% | -11.91% | $3.62B |
- XENE's peers: ACAD (Acadia Pharmaceuticals), AVXL (Anavex Life Sciences), AXSM (Axsome Therapeutics), DNLI (Denali Therapeutics), JAZZ (Jazz Pharmaceuticals), NBIX (Neurocrine Biosciences), NMRA (Neumora Therapeutics), PRAX (Praxis Precision Medicines).
Updated 2026-11-02 23:13 UTC